Kindred Biosciences Launches Mirataz™ (mirtazapine transdermal ointment)

Kindred Biosciences, Inc., a biopharmaceutical company focused on saving and improving the lives of pets, announces the commercial launch of Mirataz™ (mirtazapine transdermal ointment) for the management of weight loss in cats.

Veterinarians can now immediately order Mirataz through their preferred animal health distributor, and pre-orders are shipping. In May 2018, Mirataz was approved by the U.S. Food & Drug Administration (FDA) Center for Veterinary Medicine (CVM), making it the first and only FDA-approved transdermal medication for the management of weight loss in cats.

Survey: Opportunity for Veterinarians to Include Feline Muscle Condition Score (MCS) Assessments

In a recent survey, only 14 percent of veterinarians said they perform feline muscle condition score (MCS) evaluations during physical exams. The survey was conducted with 111 veterinarians by Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, at the 2018 Veterinary Meeting and Expo (VMX).1

5 Tips for Improving Owner Compliance

When dispensing medication for in-home treatment of feline patients, owner compliance is a concern due to the unique challenges of administering medication to cats.

“Cats have natural behaviors that may make medication administration challenging, and this can be complicated in ill cats that are also anorexic, nauseated, or vomiting,” says Christina Fernandez, DVM, MRCVS, DACVECC, Professional Services Veterinarian with Kindred Biosciences, Inc. “Palatability is also a huge factor, and most cats are finicky when it comes to food.”

On-Target Body Condition for Cats

Feline obesity is an increasingly recognized concern, but veterinarians and owners must be on alert for the flip side of the problem: unintended weight loss.

“Good nutrition and a healthy body condition are fundamental to pet health,” says Christina Fernandez, DVM, MRCVS, DACVECC, Professional Services Veterinarian with Kindred Biosciences, Inc. “There are certainly health concerns when cats are overweight, but we should also be on the lookout for unintended weight loss, which can signify an underlying disease.”1

Mirataz is indicated for the management of weight loss in cats.

Important Safety Information

Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients. Do not use in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves when handling/applying, wash hands after and avoid contact between the treated cat and people or other animals for 2 hours following application. Use with caution in cats with hepatic and kidney disease. Cat’s food intake should be monitored upon discontinuation. Safety has not been evaluated in cats less than 2 kg, less than six months of age or in breeding, pregnant or lactating cats. The most common adverse reactions observed during clinical trials were application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting. For product label, including complete safety information, click here.